!Ovarian Tumor: Early Detection and Prevention

The Most Common Ovarian Tumor: Early Detection and Prevention Strategies

Ovarian tumors encompass a heterogeneous group of neoplasms that arise from different cellular components of the ovary. For clinicians and patients alike, understanding which tumors are most common, how they present, and what can be done to detect and prevent them is essential to improving outcomes. This article reviews the epidemiology, classification, risk factors, symptoms, diagnostic evaluation, prevention strategies, and evidence-based approaches to early detection for the ovarian tumors encountered most frequently in adult women, with particular emphasis on epithelial ovarian tumors—the most common group of ovarian neoplasms in adults.

Sources referenced in this review include professional guidance and patient resources from the American College of Obstetricians and Gynecologists (ACOG), the National Institutes of Health/National Cancer Institute (NIH/NCI), the Mayo Clinic, and the Cleveland Clinic.

Overview: What is an ovarian tumor?

The ovaries are paired pelvic organs with three principal functions: production of gametes (eggs), synthesis of sex hormones (estrogen and progesterone), and local endocrine signalling. A tumor is any abnormal growth arising from cells within the ovary. Ovarian tumors are classified by the cell type of origin:

  • Epithelial tumors: arise from the surface epithelium or the cells lining inclusion cysts; this category includes benign, borderline, and malignant lesions (e.g., serous, mucinous, endometrioid, clear cell).
  • Germ cell tumors: arise from primordial germ cells and include benign and malignant entities (e.g., mature cystic teratoma, dysgerminoma).
  • Sex cord–stromal tumors: originate from ovarian stromal cells responsible for hormone production (e.g., granulosa cell tumor, Sertoli-Leydig cell tumor).

In adult women, epithelial tumors are the most common overall category of ovarian neoplasms and account for the majority of ovarian cancers. In children and adolescents, germ cell tumors are comparatively more frequent. (ACOG; NCI; Mayo Clinic)

Epidemiology and the “most common” tumor

  • Among all ovarian neoplasms in adult populations, epithelial tumors are the predominant group. Epithelial ovarian cancer constitutes about 90% of malignant ovarian tumors in adults. (ACOG; NCI)
  • The most common histologic subtype of epithelial ovarian cancer is high-grade serous carcinoma. Low-grade serous, mucinous, endometrioid, and clear cell carcinomas are less frequent but clinically important subtypes due to differences in risk factors, behavior, and treatment response. (NCI; Mayo Clinic)
  • When considering benign ovarian tumors, several types are frequent, including serous cystadenomas and mature cystic teratomas (dermoid cysts). The relative prevalence of specific benign lesions varies by age group and population cohort. (Cleveland Clinic; Mayo Clinic)

Clarifying “most common”: If the question refers to the most common malignant ovarian tumor in adult women, the answer is epithelial ovarian carcinoma, specifically high-grade serous carcinoma. If the focus is on benign ovarian tumors across reproductive-age women, mature cystic teratoma and serous cystadenoma are among the most frequently encountered benign lesions. (ACOG; Mayo Clinic; Cleveland Clinic)

Risk factors for epithelial ovarian tumors

Understanding risk factors helps clinicians identify women who might benefit from genetic counseling, enhanced surveillance, or risk-reducing strategies.

Nonmodifiable risk factors

  • Age: The risk of epithelial ovarian cancer increases with age; most cases are diagnosed in postmenopausal women. (NCI)
  • Family history and inherited mutations: Pathogenic variants in BRCA1 and BRCA2 genes greatly increase lifetime risk for ovarian and breast cancer. Lynch syndrome (hereditary nonpolyposis colorectal cancer) is associated with increased risk for endometrioid and clear cell ovarian carcinomas. A family history of ovarian or related cancers should prompt genetic evaluation. (ACOG; NCI)
  • Personal history: Prior breast cancer and certain histologic ovarian tumor precursors (e.g., endometriosis is associated with an increased risk for endometrioid and clear cell subtypes) are relevant. (NCI; Mayo Clinic)

Reproductive and hormonal factors

  • Nulliparity and infertility: Women who have never had a full-term pregnancy appear to have modestly increased risk.
  • Use of menopausal hormone therapy may modestly increase risk, particularly with long-term estrogen-alone exposure. (NCI; ACOG)

Protective factors

  • Combined oral contraceptive (COC) use: Long-term use of COCs is consistently associated with a lower risk of epithelial ovarian cancer; the protective effect persists years after discontinuation. (ACOG; NCI)
  • Tubal ligation and bilateral salpingectomy: Surgical interruption of the fallopian tubes (tubal ligation) and opportunistic bilateral salpingectomy performed at the time of other pelvic surgery are associated with reduced ovarian cancer risk. This has supported the understanding that many high-grade serous cancers originate in the fallopian tube epithelium. (ACOG; NCI)
  • Pregnancy and breastfeeding: Parity and breastfeeding have protective associations. (NCI)

Lifestyle factors

  • Smoking is associated with increased risk for mucinous ovarian tumors; obesity has been linked to modest increases in ovarian cancer risk, particularly for certain histologic types. Lifestyle modification evidence is mixed, and no single behavioral change guarantees risk elimination. (Mayo Clinic; Cleveland Clinic)

Symptoms and clinical presentation

Early-stage ovarian tumors frequently cause no specific symptoms, which contributes to delayed diagnosis. When symptomatic, presentations are often subtle or nonspecific:

Common symptoms

  • Persistent abdominal or pelvic pain
  • Increased abdominal size or persistent bloating
  • Early satiety or loss of appetite
  • Urinary urgency or frequency (from mass effect)
  • Unexplained weight loss or gain

Less common or late symptoms

  • Menstrual irregularities
  • Gastrointestinal disturbances
  • Vaginal bleeding (less typical for ovarian tumors)

Because these symptoms are common in benign conditions (irritable bowel syndrome, urinary tract infections, and functional gastrointestinal disorders), patients and clinicians must consider symptom persistence, severity, and pattern. A symptom that is new, persistent, and different from prior experience deserves evaluation. (Mayo Clinic; NCI; Cleveland Clinic)

Diagnostic evaluation: What to do if an ovarian tumor is suspected

Initial clinical assessment

  • Detailed history: age, menstrual and gynecologic history, family history of cancer (breast, ovarian, colorectal, pancreatic), prior pelvic surgery, use of hormonal therapies.
  • Physical examination: abdominal and pelvic examination; bimanual pelvic exam may detect adnexal masses but has limited sensitivity and specificity for small lesions.

Imaging

  • Transvaginal ultrasound (TVUS) is the first-line imaging modality for evaluating suspected adnexal masses in most adult women. TVUS provides information on size, morphology (solid vs cystic), septations, papillary projections, and vascular flow—features that may suggest benign vs malignant nature. (ACOG; Mayo Clinic)
  • Pelvic MRI or CT scan may be used for further characterization or staging when a mass is suspicious for malignancy. CT is commonly used for staging and detection of metastatic disease.

Serum biomarkers

  • CA-125: This tumor marker can be elevated in epithelial ovarian cancer, particularly advanced high-grade serous carcinoma. However, CA-125 is neither sufficiently sensitive nor specific to serve as a screening test for average-risk women—levels may be normal in early-stage disease and elevated in many benign conditions (endometriosis, menstruation, pelvic inflammatory disease). CA-125 is more useful in postmenopausal women and in monitoring treatment response or recurrence. (ACOG; NCI)
  • Additional biomarkers and algorithms (e.g., HE4, Risk of Malignancy Index) can assist risk stratification but are not recommended as routine screening tools for average-risk asymptomatic women. (ACOG)

When to refer

  • Any adnexal mass with suspicious features on TVUS or concerning clinical findings should prompt referral to a gynecologist, and when cancer is suspected, to a gynecologic oncologist for definitive evaluation and management. Referral is particularly urgent when the patient is postmenopausal, CA-125 is elevated, the mass is solid, or there are nodular/papillary features. (ACOG; NCI)

Screening and early detection: Current recommendations

No effective screening strategy for the general population

  • There is no evidence that routine screening for ovarian cancer in asymptomatic, average-risk women using transvaginal ultrasound, CA-125, or combined strategies reduces ovarian cancer mortality. Large randomized trials have not shown benefit and demonstrate potential harms from false-positive results and unnecessary surgeries. Therefore, professional organizations do not recommend population-wide screening. (ACOG; NCI; Mayo Clinic)

Targeted strategies for high-risk women

  • Women at significantly increased genetic risk (e.g., BRCA1/BRCA2 mutation carriers, certain Lynch syndrome carriers) should undergo genetic counseling and discussion of risk-reducing options. For high-risk women, ACOG and other professional societies recommend considering risk-reducing bilateral salpingo-oophorectomy (removal of both fallopian tubes and ovaries) after completion of childbearing—timing individualized by mutation type and family history (common timing: BRCA1 often by age 35–40; BRCA2 by age 40–45). This intervention substantially reduces ovarian and fallopian tube cancer risk. (ACOG; NCI)
  • Enhanced surveillance (e.g., periodic CA-125 and TVUS) has been used for women who decline surgery or are not yet eligible; however, surveillance has not been proven to prevent cancer-related mortality and must be individualized. (ACOG; NCI)

Shared decision-making and counseling

  • For average-risk women, counseling focuses on symptom awareness and prompt evaluation of persistent pelvic or abdominal symptoms. For high-risk women, discussions should address the balance of benefits and harms of surveillance versus risk-reducing surgery, fertility implications, menopausal consequences, and alternatives such as risk-reducing salpingectomy with delayed oophorectomy in certain clinical contexts. (ACOG)

Prevention strategies

Medical and surgical approaches with evidence of risk reduction:

  • Oral contraceptives: Long-term combined oral contraceptive use reduces epithelial ovarian cancer risk by approximately 30–50%, with protection increasing with duration of use and persisting after discontinuation. This is an important preventive consideration, particularly for women at average to moderately increased risk. (ACOG; NCI)
  • Reproductive choices: Pregnancy and breastfeeding are associated with decreased risk; however, these are personal and complex decisions and not primary prevention strategies in a public health sense. (NCI)
  • Tubal ligation and bilateral salpingectomy: Tubal ligation is associated with a reduced risk of epithelial ovarian cancer. Opportunistic bilateral salpingectomy (removal of fallopian tubes) at the time of hysterectomy or sterilization has been increasingly adopted to reduce ovarian cancer risk while retaining ovarian function. (ACOG; NCI)
  • Risk-reducing bilateral salpingo-oophorectomy (RRSO): For women with high-risk genetic mutations such as BRCA1/2, RRSO after childbearing is the most effective intervention for reducing ovarian and fallopian tube cancer incidence and mortality. It also reduces breast cancer risk if performed premenopausally in some mutation carriers. The timing of RRSO should follow clinical guidelines and individualized risk assessment. (ACOG; NCI)
  • Lifestyle modifications: Maintaining a healthy weight, smoking cessation, and a balanced diet contribute to overall cancer risk reduction, though specific evidence for ovarian cancer prevention is limited and multifactorial. (Mayo Clinic; Cleveland Clinic)

Management: Overview of treatment principles

Treatment depends on tumor type (benign vs malignant), histology, stage, patient’s age, fertility desires, and overall health.

Benign lesions

  • Many benign cysts (functional cysts, simple cystadenomas) can be managed expectantly if small and asymptomatic; surgical removal is indicated for large, symptomatic, or suspicious masses. Minimally invasive surgery (laparoscopy) is commonly used for benign adnexal masses when appropriate. (Mayo Clinic; Cleveland Clinic)

Malignant epithelial ovarian cancer

  • Primary treatment for suspected epithelial ovarian cancer generally involves comprehensive surgical staging and cytoreductive surgery performed by an experienced gynecologic oncologist. Staging includes evaluation of the peritoneal cavity, sampling of peritoneal fluid, omentectomy, and removal of visible tumor deposits. The goal of cytoreductive surgery is maximal tumor removal, as residual disease is a key prognostic factor. (ACOG; NCI)
  • Systemic therapy: Standard chemotherapy for most epithelial ovarian cancers has included platinum-based regimens (carboplatin) combined with a taxane (paclitaxel). For patients with advanced disease, neoadjuvant chemotherapy followed by interval cytoreductive surgery is an accepted approach when primary optimal cytoreduction is unlikely. (ACOG; NCI)
  • Targeted therapies and maintenance treatment: Advances include PARP inhibitors for patients with BRCA mutations or homologous recombination deficiency, anti-angiogenic agents (bevacizumab) in selected settings, and emerging immunotherapy approaches. Maintenance strategies are increasingly used to prolong progression-free survival in high-risk patients. (NCI; Mayo Clinic)
  • Fertility-sparing options: For carefully selected patients with early-stage, low-grade tumors, fertility-sparing surgery (unilateral salpingo-oophorectomy with preservation of the uterus and contralateral ovary) can be considered. These decisions require specialized counseling and multidisciplinary care to balance oncologic safety and reproductive goals. (ACOG)

Germ cell and sex cord–stromal tumors

  • Germ cell tumors (e.g., dysgerminoma, immature teratoma) often occur in adolescents and young adults and can be very responsive to chemotherapy; fertility-sparing surgery is commonly pursued when feasible.
  • Sex cord–stromal tumors may produce hormones and present with endocrine symptoms; management is surgical with adjuvant therapy individualized by stage and pathology. (NCI; Mayo Clinic)

Prognosis and the importance of stage

Stage at diagnosis is the single most important prognostic factor for epithelial ovarian cancer. Five-year survival rates vary widely by stage:

  • Early-stage disease confined to the ovaries (stage I) has substantially better outcomes, with high five-year survival rates.
  • Advanced-stage disease (stage III–IV), where cancer has spread within the peritoneal cavity or to distant organs, carries a more guarded prognosis.

Because many ovarian cancers present at an advanced stage, improving early detection and reducing incidence in high-risk groups are priorities in clinical care and research. (NCI; ACOG)

Follow-up and survivorship

Post-treatment surveillance

  • Follow-up after treatment typically includes interval history, physical and pelvic examinations, and monitoring with CA-125 in patients whose levels were elevated preoperatively. Imaging is guided by symptoms or clinical concern for recurrence. Surveillance strategies aim to detect symptomatic or radiographic recurrence when salvage therapies may be considered. (ACOG; NCI)

Long-term issues

  • Survivors may experience treatment-related effects, including menopausal symptoms after oophorectomy or chemotherapy-induced ovarian insufficiency, neuropathy from chemotherapy, fatigue, and psychosocial impacts. Management includes hormone therapy considerations where appropriate, symptom control, fertility counseling, and referrals to supportive care resources. (Mayo Clinic; Cleveland Clinic)

Genetic counseling and testing

Indications for genetic evaluation

  • Personal or family history of ovarian, breast (especially early-onset), pancreatic, or certain colorectal cancers.
  • Diagnosis of epithelial ovarian cancer at any age should prompt referral for genetic counseling and germline testing, given implications for therapy (e.g., PARP inhibitors) and for cascade testing of relatives. (ACOG; NCI)

Implications of positive results

  • Identification of a pathogenic variant (e.g., BRCA1/2) changes clinical management: consideration of risk-reduction surgery, informed choices about chemotherapy and targeted therapies, and recommendations for relatives regarding testing and preventive care. (ACOG; NCI)

Practical guidance for patients and clinicians

For patients

  • Know your baseline pelvic and abdominal health. Report new, persistent, or unusual symptoms such as bloating, pelvic pain, increased abdominal size, early satiety, or urinary frequency lasting more than a few weeks to your healthcare provider. While these symptoms are commonly caused by benign conditions, persistent symptoms warrant evaluation. (Mayo Clinic; NCI)
  • Discuss family cancer history with your clinician; if there is a strong family history of ovarian or early breast cancer, ask about referral to genetic counseling. (ACOG)
  • Consider contraceptive options and reproductive planning in the context of ovarian cancer risk reduction if applicable; long-term use of combined oral contraceptives reduces ovarian cancer risk. Decisions should be individualized with a clinician. (ACOG; NCI)

For clinicians

  • Maintain a high index of suspicion in postmenopausal patients with adnexal masses or persistent pelvic/abdominal symptoms.
  • Use transvaginal ultrasound and CA-125 selectively for evaluation, and refer suspicious masses to a gynecologic oncologist for definitive management.
  • Offer genetic counseling and germline testing to all patients diagnosed with epithelial ovarian cancer and to those with a significant family history. (ACOG; NCI)

Research directions and future perspectives

Ongoing research aims to:

  • Improve understanding of tumor origins (e.g., fallopian tube as a source of many high-grade serous carcinomas) to inform prevention strategies.
  • Develop effective screening tests for early detection in high-risk and general populations, including biomarker panels and advanced imaging or molecular diagnostics.
  • Personalize therapy through genomic profiling, targeted agents, and immunotherapy to improve outcomes and reduce toxicity.
  • Investigate chemoprevention, lifestyle interventions, and optimal strategies for risk reduction in diverse populations. (NCI; ACOG)

Summary

  • Epithelial ovarian tumors are the most common category of ovarian neoplasms in adults; high-grade serous carcinoma is the most common and most lethal epithelial subtype.
  • Early-stage disease has a much better prognosis, but early detection is challenging because symptoms can be vague and nonspecific.
  • There is no recommended population-wide screening test for ovarian cancer. High-risk women (e.g., BRCA mutation carriers) should be identified through family history and offered genetic counseling and discussion of risk-reducing options, such as bilateral salpingo-oophorectomy.
  • Preventive strategies with evidence of risk reduction include combined oral contraceptives, tubal ligation/opportunistic salpingectomy, and, for high-risk women, risk-reducing salpingo-oophorectomy.
  • Evaluation of suspected adnexal masses involves targeted history, physical exam, transvaginal ultrasound, selective use of CA-125, and timely referral to gynecologic oncology when indicated.
  • Management requires individualized, multidisciplinary care; advances in surgery, chemotherapy, and targeted therapy have improved outcomes but early detection and prevention remain priorities.

For authoritative, patient-oriented information and professional guidance, consult resources from:

  • American College of Obstetricians and Gynecologists (ACOG): Practice bulletins on adnexal masses and hereditary cancer syndromes.
  • National Cancer Institute (NCI/NIH): Ovarian cancer overview and clinical trials.
  • Mayo Clinic: Patient education on ovarian tumors and symptoms.
  • Cleveland Clinic: Clinical information on ovarian cysts and tumors.

References and further reading

  • ACOG Committee Opinions and Practice Bulletins on adnexal masses, hereditary cancer syndromes, and ovarian cancer. (www.acog.org)
  • National Cancer Institute: Ovarian Cancer—Overview and Treatment. (www.cancer.gov)
  • Mayo Clinic: Ovarian Cancer—Symptoms and Causes. (www.mayoclinic.org)
  • Cleveland Clinic: Ovarian Cysts and Tumors. (my.clevelandclinic.org)

If you have concerns about symptoms, a family history of cancer, or the need for genetic counseling, schedule a consultation with your healthcare provider or a gynecologic oncologist to discuss individualized risk assessment and management options.